Thierry Brue

List of Publications by Year
in descending order

275 papers	14,604 citations	15466 65 h-index	24915 109 g-index
359 all docs	359 docs citations	359 times ranked	8282 citing authors

#	Article	IF	Citations
1	Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology, 2006, 65, 265-273.	1.2	720
2	A Pituitary Cell-Restricted T Box Factor, Tpit, Activates POMC Transcription in Cooperation with Pitx Homeoproteins. Cell, 2001, 104, 849-859.	13.5	491
3	A new prognostic clinicopathological classification of pituitary adenomas: a multicentric caseâ€“control study of 410 patients with 8Âyears post-operative follow-up. Acta Neuropathologica, 2013, 126, 123-135.	3.9	395
4	Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E373-E383.	1.8	323
5	Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes and Endocrinology,the, 2014, 2, 875-884.	5.5	309
6	Aryl Hydrocarbon Receptor-Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1891-1896.	1.8	283
7	Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. European Journal of Endocrinology, 2015, 172, 195-204.	1.9	232
8	Ketoconazole in Cushing's Disease: Is It Worth a Try?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1623-1630.	1.8	231
9	Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1589-1597.	1.8	229
10	Clinical Characterization of Familial Isolated Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3316-3323.	1.8	217
11	Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes and Development, 2006, 20, 2871-2886.	2.7	213
12	Outcome of Gamma Knife Radiosurgery in 82 Patients with Acromegaly: Correlation with Initial Hypersecretion. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4483-4488.	1.8	209
13	Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4592-4599.	1.8	202
14	Macroprolactinemia Revisited: A Study on 106 Patients. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 581-588.	1.8	195
15	Human and mouse TPIT gene mutations cause early onset pituitary ACTH deficiency. Genes and Development, 2003, 17, 711-716.	2.7	190
16	Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology, 2012, 167, 651-662.	1.9	173
17	Gamma knife radiosurgery is a successful adjunctive treatment in Cushingâ€™s disease. European Journal of Endocrinology, 2007, 156, 91-98.	1.9	166
18	Long-Term Results of Stereotactic Radiosurgery in Secretory Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3400-3407.	1.8	164

#	Article	IF	Citations
19	Acromegaly at diagnosis in 3173 patients from the LiÃ¨ge Acromegaly Survey (LAS) Database. Endocrine-Related Cancer, 2017, 24, 505-518.	1.6	164
20	Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. European Journal of Endocrinology, 2008, 158, 91-99.	1.9	158
21	Spontaneous fertility and pregnancy outcomes amongst 480 women with Turner syndrome. Human Reproduction, 2016, 31, 782-788.	0.4	158
22	Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocrine-Related Cancer, 2015, 22, 745-757.	1.6	155
23	Epilepsy related to hypothalamic hamartomas: surgical management with special reference to gamma knife surgery. Child's Nervous System, 2006, 22, 881-895.	0.6	152
24	High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. European Journal of Endocrinology, 2011, 165, 509-515.	1.9	152
25	Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis. European Journal of Endocrinology, 2013, 168, 533-541.	1.9	146
26	Prognostic Factors in Prolactin Pituitary Tumors: Clinical, Histological, and Molecular Data from a Series of 94 Patients with a Long Postoperative Follow-Up. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1708-1716.	1.8	144
27	Merits and pitfalls of mifepristone in Cushing's syndrome. European Journal of Endocrinology, 2009, 160, 1003-1010.	1.9	141
28	Molecular mechanisms of pituitary organogenesis: In search of novel regulatory genes. Molecular and Cellular Endocrinology, 2010, 323, 4-19.	1.6	140
29	Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. European Journal of Endocrinology, 2011, 164, 877-884.	1.9	140
30	Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncology, The, 2014, 15, 648-655.	5.1	137
31	Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocrine-Related Cancer, 2009, 16, 1029-1043.	1.6	134
32	Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. European Journal of Endocrinology, 2017, 176, 645-655.	1.9	133
33	Genetic Screening of Combined Pituitary Hormone Deficiency: Experience in 195 Patients. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3329-3336.	1.8	132
34	Mutations in theAryl Hydrocarbon Receptor Interacting ProteinGene Are Not Highly Prevalent among Subjects with Sporadic Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1952-1955.	1.8	132
35	Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clinical Endocrinology, 2012, 76, 769-775.	1.2	125
36	A Comparative Phenotypic Study of Kallmann Syndrome Patients Carrying Monoallelic and Biallelic Mutations in the Prokineticin 2 or Prokineticin Receptor 2 Genes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 659-669.	1.8	124

#	Article	IF	Citations
37	The selector gene Pax7 dictates alternate pituitary cell fates through its pioneer action on chromatin remodeling. Genes and Development, 2012, 26, 2299-2310.	2.7	124
38	Congenital Isolated Adrenocorticotropin Deficiency: An Underestimated Cause of Neonatal Death, Explained byTPITGene Mutations. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1323-1331.	1.8	116
39	Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 981-995.	0.2	116
40	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 17-26.	5.5	116
41	THERAPY OF ENDOCRINE DISEASE: Outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. European Journal of Endocrinology, 2015, 172, R227-R239.	1.9	114
42	PROP1 Gene Screening in Patients with Multiple Pituitary Hormone Deficiency Reveals Two Sites of Hypermutability and a High Incidence of Corticotroph Deficiency. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4529-4535.	1.8	112
43	Novel Mutations within the POU1F1 Gene Associated with Variable Combined Pituitary Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4762-4770.	1.8	111
44	Acromegaly and Pregnancy: A Retrospective Multicenter Study of 59 Pregnancies in 46 Women. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4680-4687.	1.8	111
45	Gamma Knife Surgery for Epilepsy Related to Hypothalamic Hamartomas. Seminars in Pediatric Neurology, 2007, 14, 73-79.	1.0	109
46	Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. European Journal of Endocrinology, 1996, 135, 413-420.	1.9	104
47	Role of stereotactic radiosurgery in the management of pituitary adenomas. Nature Reviews Endocrinology, 2010, 6, 214-223.	4.3	99
48	Clinical Outcome, Hormonal Status, Gonadotrope Axis, and Testicular Function in 219 Adult Men Born With Classic 21-Hydroxylase Deficiency. A French National Survey. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2303-2313.	1.8	94
49	Pituitary Stem Cell Update and Potential Implications for Treating Hypopituitarism. Endocrine Reviews, 2011, 32, 453-471.	8.9	86
50	Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes and Endocrinology,the, 2019, 7, 213-220.	5.5	86
51	Desmopressin test during petrosal sinus sampling: a valuable tool to discriminate pituitary or ectopic ACTH-dependent Cushingâ€™s syndrome. European Journal of Endocrinology, 2007, 157, 271-277.	1.9	84
52	Mutations in NFKB2and potential genetic heterogeneity in patients with DAVID syndrome, having variable endocrine and immune deficiencies. BMC Medical Genetics, 2014, 15, 139.	2.1	84
53	T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocrine-Related Cancer, 2016, 23, 871-881.	1.6	82
54	Prolactinomas and Resistance to Dopamine Agonists. Hormone Research, 1992, 38, 84-89.	1.8	79

#	Article	IF	Citations
55	Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocrine-Related Cancer, 2015, 22, 169-177.	1.6	78
56	Pituitary stalk interruption syndrome in 83 patients: novel HESX1 mutation and severe hormonal prognosis in malformative forms. European Journal of Endocrinology, 2011, 164, 457-465.	1.9	77
57	Cooperation between Cyclin E and p27Kip1 in Pituitary Tumorigenesis. Molecular Endocrinology, 2010, 24, 1835-1845.	3.7	76
58	A Familial Form of Congenital Hypopituitarism Due to aPROP1Mutation in a Large Kindred: Phenotypic andin VitroFunctional Studies. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5779-5786.	1.8	75
59	A Novel Dysfunctional LHX4 Mutation with High Phenotypical Variability in Patients with Hypopituitarism. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2790-2799.	1.8	73
60	Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Endocrine-Related Cancer, 2012, 19, 233-241.	1.6	72
61	Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions. Journal of Clinical Endocrinology and Metabolism, 1992, 75, 540-546.	1.8	70
62	PROKR2 Variants in Multiple Hypopituitarism with Pituitary Stalk Interruption. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1068-E1073.	1.8	68
63	MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis. European Journal of Endocrinology, 2019, 181, R107-R118.	1.9	68
64	Phenotypic Homogeneity and Genotypic Variability in a Large Series of Congenital Isolated ACTH-Deficiency Patients with TPIT Gene Mutations. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E486-E495.	1.8	67
65	MANAGEMENT OF ENDOCRINE DISEASE: Management of Cushingâ€™s syndrome during pregnancy: solved and unsolved questions. European Journal of Endocrinology, 2018, 178, R259-R266.	1.9	67
66	A new mutation of the gene encoding the transcription factor Pit-1 is responsible for combined pituitary hormone deficiency. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2790-2796.	1.8	67
67	Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.. Journal of Clinical Endocrinology and Metabolism, 1992, 74, 577-584.	1.8	66
68	Defective Retinoic Acid Regulation of the Pit-1 Gene Enhancer: A Novel Mechanism of Combined Pituitary Hormone Deficiency. Molecular Endocrinology, 1999, 13, 476-484.	3.7	66
69	Pituitary Transcription Factors: From Congenital Deficiencies to Gene Therapy. Journal of Neuroendocrinology, 2006, 18, 633-642.	1.2	66
70	A new mutation of the gene encoding the transcription factor Pit-1 is responsible for combined pituitary hormone deficiency.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2790-2796.	1.8	65
71	Gamma Knife Surgery for Epilepsy Related to Hypothalamic Hamartomas. , 2004, 91, 33-50.		65
72	Macroprolactinemia Revisited: A Study on 106 Patients. , 0, .		65

#	Article	IF	Citations
73	Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. European Journal of Endocrinology, 2018, 179, 419-427.	1.9	64
74	An Uncommon Phenotype with Familial Central Hypogonadism Caused by a Novel PROP1 Gene Mutant Truncated in the Transactivation Domain. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4880-4887.	1.8	61
75	Aggressive pituitary tumours and pituitary carcinomas. Nature Reviews Endocrinology, 2021, 17, 671-684.	4.3	60
76	Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine, 2016, 53, 210-219.	1.1	59
77	Radiotherapy and radiosurgery in acromegaly. Pituitary, 2009, 12, 3-10.	1.6	56
78	Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. Journal of Clinical Endocrinology and Metabolism, 1992, 74, 577-584.	1.8	55
79	Differential Regulation of Proopiomelanocortin and Pituitary-Restricted Transcription Factor (TPIT), a New Marker of Normal and Adenomatous Human Corticotrophs. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3050-3056.	1.8	54
80	Deficit in Anterior Pituitary Function and Variable Immune Deficiency (DAVID) in Children Presenting with Adrenocorticotropin Deficiency and Severe Infections. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E121-E128.	1.8	54
81	Management of hyperglycaemia in Cushing's disease: Expertsâ€™ proposals on the use of pasireotide. Diabetes and Metabolism, 2013, 39, 34-41.	1.4	54
82	Bilateral adrenalectomy in the 21st century: when to use it for hypercortisolism?. Endocrine-Related Cancer, 2016, 23, R131-R142.	1.6	54
83	MANAGEMENT OF ENDOCRINE DISEASE: Outcome of adrenal sparing surgery in heritable pheochromocytoma. European Journal of Endocrinology, 2016, 174, R9-R18.	1.9	54
84	Medical Treatment of Cushingâ€™s Syndrome: Glucocorticoid Receptor Antagonists and Mifepristone. Neuroendocrinology, 2010, 92, 125-130.	1.2	53
85	Pharmacokinetic Evidence for Suboptimal Treatment of Adrenal Insufficiency with Currently Available Hydrocortisone Tablets. Clinical Pharmacokinetics, 2010, 49, 455-463.	1.6	53
86	Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. Endocrine-Related Cancer, 2014, 21, 691-704.	1.6	53
87	High mortality within 90 days of diagnosis in patients with Cushingâ€™s syndrome: results from the ERCUSYN registry. European Journal of Endocrinology, 2019, 181, 461-472.	1.9	53
88	TheCables1Gene in Glucocorticoid Regulation of Pituitary Corticotrope Growth and Cushing Disease. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 513-522.	1.8	52
89	Development of ACRODATÂ®, a new software medical device to assess disease activity in patients with acromegaly. Pituitary, 2017, 20, 692-701.	1.6	51
90	Signs and symptoms of acromegaly at diagnosis: the physicianâ€™s and the patientâ€™s perspectives in the ACRO-POLIS study. Endocrine, 2019, 63, 120-129.	1.1	51

#	Article	IF	Citations
91	DIAGNOSIS OF ENDOCRINE DISEASE: Pituitary stalk interruption syndrome: etiology and clinical manifestations. European Journal of Endocrinology, 2019, 181, R199-R209.	1.9	50
92	MECHANISMS IN ENDOCRINOLOGY: An update in the genetic aetiologies of combined pituitary hormone deficiency. European Journal of Endocrinology, 2016, 174, R239-R247.	1.9	49
93	Prevalence ofKISS1 Receptormutations in a series of 603 patients with normosmic congenital hypogonadotrophic hypogonadism and characterization of novel mutations: a single-centre study. Human Reproduction, 2016, 31, 1363-1374.	0.4	47
94	Insulin-Induced Lipoatrophy in Type I Diabetes: A possible tumor necrosis factor-Â-mediated dedifferentiation of adipocytes. Diabetes Care, 1996, 19, 1283-1285.	4.3	46
95	Cushingâ€™s disease. Orphanet Journal of Rare Diseases, 2012, 7, 41.	1.2	46
96	Hepatic safety of ketoconazole in Cushingâ€™s syndrome: results of a Compassionate Use Programme in France. European Journal of Endocrinology, 2018, 178, 447-458.	1.9	46
97	The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome. Current Opinion in Endocrinology, Diabetes and Obesity, 2012, 19, 295-299.	1.2	45
98	A Combined Dexamethasone Desmopressin Test as an Early Marker of Postsurgical Recurrence in Cushingâ€™s Disease. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1897-1903.	1.8	44
99	Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients. Clinical Endocrinology, 2013, 78, 263-270.	1.2	44
100	The desmopressin test as a predictive factor of outcome after pituitary surgery for Cushing's disease. European Journal of Endocrinology, 2004, 151, 727-733.	1.9	43
101	Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Molecular and Cellular Endocrinology, 2008, 286, 206-213.	1.6	43
102	Delayed diagnosis of Sheehan's syndrome in a developed country: a retrospective cohort study. European Journal of Endocrinology, 2013, 169, 431-438.	1.9	43
103	Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. European Journal of Endocrinology, 2017, 176, 613-624.	1.9	42
104	Somatostatin Receptor sst2 Decreases Cell Viability and Hormonal Hypersecretion and Reverses Octreotide Resistance of Human Pituitary Adenomas. Cancer Research, 2008, 68, 10163-10170.	0.4	39
105	The risks of overlooking the diagnosis of secreting pituitary adenomas. Orphanet Journal of Rare Diseases, 2016, 11, 135.	1.2	39
106	Activin Inhibits the Human Pit-1 Gene Promoter through the p38 Kinase Pathway in a Smad-Independent Manner. Endocrinology, 2006, 147, 4351-4362.	1.4	38
107	Diagnosis andÂmanagement ofÂhyperprolactinemia: expert consensus â€“ French Society ofÂEndocrinology. Annales D'Endocrinologie, 2007, 68, 58-64.	0.6	38
108	GsÎ± overexpression and loss of GsÎ± imprinting in human somatotroph adenomas: Association with tumor size and response to pharmacologic treatment. International Journal of Cancer, 2007, 121, 1245-1252.	2.3	38

#	Article	IF	Citations
109	Combined pituitary hormone deficiency: current and future status. Journal of Endocrinological Investigation, 2015, 38, 1-12.	1.8	37
110	Preoperative medical treatment in Cushingâ€™s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. European Journal of Endocrinology, 2018, 178, 399-409.	1.9	37
111	Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. European Journal of Endocrinology, 2020, 182, 583.	1.9	36
112	Corticotroph tumor progression after bilateral adrenalectomy (Nelsonâ€™s syndrome): systematic review and expert consensus recommendations. European Journal of Endocrinology, 2021, 184, P1-P16.	1.9	32
113	More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. European Journal of Endocrinology, 2021, 185, 525-538.	1.9	32
114	A conservative management is preferable in milder forms of pituitary tumor apoplexy. Journal of Endocrinological Investigation, 2011, 34, 502-9.	1.8	32
115	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.1	31
116	Immunoradiometric analysis of circulating human glycosylated and nonglycosylated prolactin forms: spontaneous and stimulated secretions.. Journal of Clinical Endocrinology and Metabolism, 1992, 75, 1338-1344.	1.8	30
117	Pituitary hormone deficiencies due to transcription factor gene alterations. Growth Hormone and IGF Research, 2004, 14, 442-448.	0.5	29
118	Combined Pituitary Hormone Deficiency due to the F135C Human Pit-1 (Pituitary-Specific Factor 1) Gene Mutation: Functional and Structural Correlates. Molecular Endocrinology, 2001, 15, 411-420.	3.7	28
119	Etiological diagnosis ofÂhyperprolactinemia. Annales D'Endocrinologie, 2007, 68, 98-105.	0.6	28
120	ISL1 Is Necessary for Maximal Thyrotrope Response to Hypothyroidism. Molecular Endocrinology, 2015, 29, 1510-1521.	3.7	28
121	Quantitative 18F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 278-282.	3.3	28
122	French consensus on the management of acromegaly. Annales D'Endocrinologie, 2009, 70, 92-106.	0.6	27
123	MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. European Journal of Endocrinology, 2017, 176, 323-328.	1.9	27
124	A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. European Journal of Endocrinology, 2018, 179, 97-108.	1.9	27
125	Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocrine Connections, 2020, 9, 1178-1190.	0.8	27
126	Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. Annales D'Endocrinologie, 2012, 73, 225-229.	0.6	26

#	Article	IF	Citations
127	Bilateral neck exploration in patients with primary hyperparathyroidism and discordant imaging results: a single-centre study. European Journal of Endocrinology, 2014, 170, 719-725.	1.9	26
128	Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2964-2974.	1.8	26
129	The Role of CBP/p300 Interactions and Pit-1 Dimerization in the Pathophysiological Mechanism of Combined Pituitary Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 239-247.	1.8	25
130	PITX2 AND PITX1 Regulate Thyrotroph Function and Response to Hypothyroidism. Molecular Endocrinology, 2011, 25, 1950-1960.	3.7	25
131	Immunoradiometric analysis of circulating human glycosylated and nonglycosylated prolactin forms: spontaneous and stimulated secretions. Journal of Clinical Endocrinology and Metabolism, 1992, 75, 1338-1344.	1.8	25
132	Lanreotide for the treatment of acromegaly. Advances in Therapy, 2009, 26, 600-612.	1.3	24
133	Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?. Oncotarget, 2017, 8, 41044-41063.	0.8	24
134	Pseudotumor of the Pituitary due to PROP-1 Deletion. Journal of Pediatric Endocrinology and Metabolism, 2002, 15, 95-101.	0.4	23
135	Familial pituitary adenomas. Annales D'Endocrinologie, 2010, 71, 479-485.	0.6	23
136	Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy. Endocrine, 2019, 63, 563-572.	1.1	23
137	High-throughput splicing assays identify missense and silent splice-disruptive POU1F1 variants underlying pituitary hormone deficiency. American Journal of Human Genetics, 2021, 108, 1526-1539.	2.6	23
138	X chromosome gene dosage as a determinant of congenital malformations and of age-related comorbidity risk in patients with Turner syndrome, from childhood to early adulthood. European Journal of Endocrinology, 2019, 180, 397-406.	1.9	23
139	Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing's syndrome. Annales D'Endocrinologie, 2022, 83, 119-141.	0.6	23
140	Inactivation of PITX2 Transcription Factor Induced Apoptosis of Gonadotroph Tumoral Cells. Endocrinology, 2011, 152, 3884-3892.	1.4	22
141	Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY. Annales D'Endocrinologie, 2015, 76, 664-670.	0.6	22
142	Looking beyond the thyroid: advances in the understanding of pheochromocytoma and hyperparathyroidism phenotypes in MEN2 and of non-MEN2 familial forms. Endocrine-Related Cancer, 2018, 25, T15-T28.	1.6	22
143	Clinical lessons learned in constitutional hypopituitarism from two decades of experience in a large international cohort. Clinical Endocrinology, 2021, 94, 277-289.	1.2	22
144	Identification and Functional Analysis of the Novel S179R POU1F1 Mutation Associated with Combined Pituitary Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4981-4987.	1.8	21

#	Article	IF	Citations
145	Successful IVF pregnancy despite inadequate ovarian steroidogenesis due to congenital lipoid adrenal hyperplasia (CLAH): a case report. Human Reproduction, 2016, 31, 2609-2612.	0.4	21
146	A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues. European Journal of Endocrinology, 2017, 176, 421-431.	1.9	21
147	MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives. Endocrine, 2020, 69, 496-503.	1.1	21
148	Severe fibromyalgia after hypophysectomy for cushing's disease. Arthritis and Rheumatism, 1991, 34, 493-495.	6.7	20
149	ACROSTUDY: Status Update on 469 Patients. Hormone Research in Paediatrics, 2009, 71, 34-38.	0.8	20
150	Comparative Validation of the Growth Hormone-Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency Using a Growth Hormone Assay Conforming to Recent International Recommendations. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3684-3692.	1.8	20
151	Pre-surgical medical treatment, a major prognostic factor for long-term remission in acromegaly. Pituitary, 2018, 21, 615-623.	1.6	20
152	Acromegaly in Carney complex. Pituitary, 2019, 22, 456-466.	1.6	20
153	Postoperative followâ€up of Cushing's disease using cortisol, desmopressin and coupled dexamethasoneâ€desmopressin tests: a headâ€toâ€head comparison. Clinical Endocrinology, 2015, 83, 216-222.	1.2	19
154	Active Cushing syndrome patients have increased ectopic fat deposition and bone marrow fat content compared to cured patients and healthy subjects: a pilot 1H-MRS study. European Journal of Endocrinology, 2018, 179, 307-317.	1.9	19
155	Lessons Learned from 15 Years of KIMS and 5 Years of ACROSTUDY. Hormone Research in Paediatrics, 2011, 76, 33-38.	0.8	18
156	GPR101 Mutations are not a Frequent Cause of Congenital Isolated Growth Hormone Deficiency. Hormone and Metabolic Research, 2016, 48, 389-393.	0.7	18
157	Cushing Syndrome Is Associated With Subclinical LV Dysfunction and Increased Epicardial Adipose Tissue. Journal of the American College of Cardiology, 2018, 72, 2276-2277.	1.2	18
158	Surgical indications for pituitary tumors during pregnancy: a literature review. Pituitary, 2020, 23, 189-199.	1.6	18
159	The risks of medical treatment of prolactinoma. Annales D'Endocrinologie, 2021, 82, 15-19.	0.6	18
160	Radiotherapy as a tool for the treatment of Cushingâ€™s disease. European Journal of Endocrinology, 2019, 180, D9-D18.	1.9	18
161	Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY. European Journal of Endocrinology, 2009, 161, S11-S17.	1.9	17
162	Case seminar: a young female with acute hyponatremia and a sellar mass. Endocrine, 2011, 40, 325-331.	1.1	17

#	Article	IF	Citations
163	Genetic causes of combined pituitary hormone deficiencies in humans. Annales D'Endocrinologie, 2012, 73, 53-55.	0.6	17
164	Heterozygous LHX3 mutations may lead to a mild phenotype of combined pituitary hormone deficiency. European Journal of Human Genetics, 2019, 27, 216-225.	1.4	17
165	Adrenal Myelolipoma: An Unusual Cause of Bilateral Highly 18F-FDG-Avid Adrenal Masses. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2577-2578.	1.8	16
166	Successful pregnancies and healthy live births using frozen-thawed sperm retrieved by a new modified Hotchkiss procedure in males with retrograde ejaculation: first case series. Basic and Clinical Andrology, 2015, 25, 5.	0.8	16
167	Pilot Neonatal Screening Program for Central Congenital Hypothyroidism: Evidence of Significant Detection. Hormone Research in Paediatrics, 2017, 88, 274-280.	0.8	16
168	Lack of functional remission in Cushingâ€™s syndrome. Endocrine, 2018, 61, 518-525.	1.1	16
169	R31C GNRH1 Mutation and Congenital Hypogonadotropic Hypogonadism. PLoS ONE, 2013, 8, e69616.	1.1	16
170	Macroprolactinemia: A Cause of Hyperprolactinemia in Childhood. Journal of Pediatric Endocrinology and Metabolism, 1997, 10, 411-7.	0.4	15
171	Does first-line surgery still have its place in the treatment of acromegaly?. Annales D'Endocrinologie, 2009, 70, 107-112.	0.6	15
172	Identifying the Deleterious Effect of Rare LHX4 Allelic Variants, a Challenging Issue. PLoS ONE, 2015, 10, e0126648.	1.1	15
173	Prolactin Isoforms Secreted by Human Prolactinomas. Hormone Research, 1992, 38, 164-170.	1.8	14
174	Evidence for an internal and functional circadian clock in rat pituitary cells. Molecular and Cellular Endocrinology, 2014, 382, 888-898.	1.6	14
175	An observational study on adrenal insufficiency in a French tertiary centre: Real life versus theory. Annales D'Endocrinologie, 2015, 76, 1-8.	0.6	14
176	Parasellar Meningiomas. Neuroendocrinology, 2020, 110, 780-796.	1.2	14
177	Clinical characteristics of familial hypocalciuric hypercalcaemia type 1: A multicentre study of 77 adult patients. Clinical Endocrinology, 2020, 93, 248-260.	1.2	14
178	ESE audit on management of adult growth hormone deficiency in clinical practice. European Journal of Endocrinology, 2021, 184, 323-334.	1.9	14
179	Markers of tumor invasion are major predictive factors for the long-term outcome of corticotroph microadenomas treated by transsphenoidal adenomectomy. European Journal of Endocrinology, 2000, 143, 761-768.	1.9	13
180	Prolactinoma surgery. Annales D'Endocrinologie, 2007, 68, 118-119.	0.6	13

#	Article	IF	Citations
181	Detection of genetic hypopituitarism in an adult population of idiopathic pituitary insufficiency patients with growth hormone deficiency. Pituitary, 2011, 14, 208-216.	1.6	13
182	Gamma Knife radiosurgery for hypothalamic hamartoma preserves endocrine functions. Epilepsia, 2017, 58, 72-76.	2.6	13
183	Functioning gonadotroph adenoma with severe ovarian hyperstimulation syndrome: A new emergency in pituitary adenoma surgery? Surgical considerations and literature review. Annales D'Endocrinologie, 2019, 80, 122-127.	0.6	13
184	Osilodrostat in Cushing's disease: The risk of delayed adrenal insufficiency should be carefully monitored. Clinical Endocrinology, 2023, 98, 629-630.	1.2	13
185	Somatostatin receptor ligands induce TSH deficiency in thyrotropin-secreting pituitary adenoma. European Journal of Endocrinology, 2021, 184, 1-8.	1.9	13
186	Pituitary deficiency after brain radiation therapy. Annales D'Endocrinologie, 2006, 67, 303-309.	0.6	12
187	Truncation of PITX2 differentially affects its activity on physiological targets. Journal of Molecular Endocrinology, 2011, 46, 9-19.	1.1	12
188	Increased Risk of Persistent Glucose Disorders After Control of Acromegaly. Journal of the Endocrine Society, 2017, 1, 1531-1539.	0.1	12
189	Unilateral agenesis of internal carotid artery associated with congenital combined pituitary hormone deficiency and pituitary stalk interruption without HESX1, LHX4 or OTX2 mutation: a case report. Pituitary, 2012, 15, 81-86.	1.6	11
190	Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults. European Journal of Endocrinology, 2018, 179, 169-179.	1.9	11
191	Germinal defects of SDHx genes in patients with isolated pituitary adenoma. European Journal of Endocrinology, 2020, 183, 369-379.	1.9	11
192	Evaluation of an individualized education program in pituitary diseases: a pilot study. European Journal of Endocrinology, 2020, 183, 551-559.	1.9	11
193	Whole exome sequencing in a cohort of familial premature ovarian insufficiency cases reveals a broad array of pathogenic or likely pathogenic variants in 50% of families. Fertility and Sterility, 2022, 117, 843-853.	0.5	11
194	Enlarged adenomectomy for enclosed prolactinomas: A preliminary study of 26 cases. Acta Neurochirurgica, 1990, 103, 92-98.	0.9	10
195	Glycosylated and nonâ€glycosylated prolactin forms are increased after opioid administration as part of surgical anaesthesia. Clinical Endocrinology, 1995, 43, 213-217.	1.2	10
196	Pattern of Prolactin Diurnal Secretion in Normal Humans; Evidence for Nonlinear Dynamics. Neuroendocrinology, 1995, 62, 444-453.	1.2	10
197	Inactivation of Transcription Factor Pit-1 to Target Tumoral Somatolactotroph Cells. Human Gene Therapy, 2012, 23, 104-114.	1.4	10
198	In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells. Endocrine-Related Cancer, 2016, 23, 509-519.	1.6	10

#	Article	IF	Citations
199	Prolactin immunoassay: does the high-dose hook effect still exist?. Pituitary, 2022, 25, 653-657.	1.6	10
200	Large Adrenal Incidentalomas Require a Dedicated Diagnostic Procedure. Endocrine Practice, 2019, 25, 669-677.	1.1	9
201	Meningiomas in patients with long-term exposition to progestins: Characteristics and outcome. Neurochirurgie, 2021, 67, 556-563.	0.6	9
202	3D-FT thin sections MRI of prolactin-secreting pituitary microadenomas. Neuroradiology, 1994, 36, 376-379.	1.1	8
203	Hypopituitarism in Patients with Blepharophimosis and <i>FOXL2</i> Mutations. Hormone Research in Paediatrics, 2020, 93, 30-39.	0.8	8
204	Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege Acromegaly Survey database. Endocrine, 2020, 70, 134-142.	1.1	8
205	Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study. Endocrine, 2021, 71, 158-167.	1.1	8
206	Current clinical practice for thromboprophylaxis management in patients with Cushingâ€™s syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN). Orphanet Journal of Rare Diseases, 2022, 17, 178.	1.2	8
207	An ultrarapid prognostic index in microprolactinoma surgery. Journal of Neurosurgery, 1999, 90, 1037-1041.	0.9	7
208	A Neonatal Form of Isolated ACTH Deficiency Frequently Associated with Tpit Gene Mutations. Endocrine Research, 2004, 30, 943-944.	0.6	7
209	Consensus franÃ§ais sur la prise en charge de lâ€™acromÃ©galie. Annales D'Endocrinologie, 2009, 70, e9-e22.	0.6	7
210	Clinical, Biological and Genetic Analysis of 8 Cases of Congenital Isolated Adrenocorticotrophic Hormone (ACTH) Deficiency. PLoS ONE, 2011, 6, e26516.	1.1	7
211	Pituitary apoplexy after somatostatin analogue administration: coincidental or causative?. Clinical Endocrinology, 2014, 81, 471-473.	1.2	7
212	A monocentric experience of growth hormone replacement therapy in adult patients. Annales D'Endocrinologie, 2014, 75, 176-183.	0.6	7
213	Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells. Pituitary, 2021, 24, 351-358.	1.6	7
214	Transcranial approach in giant pituitary adenomas: results and outcome in a modern series. Journal of Neurosurgical Sciences, 2020, 64, 25-36.	0.3	7
215	Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience. Pituitary, 2022, 25, 420-432.	1.6	7
216	Gamma Knife radiosurgery in pituitary adenomas: Why, who, and how to treat?. Discovery Medicine, 2010, 10, 107-11.	0.5	7

#	Article	IF	Citations
217	Current and Emerging Medical Therapies in Pituitary Tumors. Journal of Clinical Medicine, 2022, 11, 955.	1.0	7
218	Lessons from monogenic causes of growth hormone deficiency. Annales D'Endocrinologie, 2017, 78, 77-79.	0.6	6
219	Clinical management of difficult to treat macroprolactinomas. Expert Review of Endocrinology and Metabolism, 2019, 14, 179-192.	1.2	6
220	Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312) Tj ETQq0 0 0 rgBT /Overlock 10	0.6	6
221	Synergistic cortisol suppression by ketoconazoleâ€“osilodrostat combination therapy. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.2	6
222	Impact of Cushing's syndrome on fertility and pregnancy. Annales D'Endocrinologie, 2022, 83, 188-190.	0.6	6
223	Ghrelin Receptor (GHS-R1a) and Its Constitutive Activity in Somatotroph Adenomas: A New Co-targeting Therapy Using GHS-R1a Inverse Agonists and Somatostatin Analogs. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2463-E2471.	1.8	5
224	Pre-term birth in women exposed to Cushingâ€™s disease: the baby-cush study. European Journal of Endocrinology, 2021, 184, 469-476.	1.9	5
225	Novel mechanism of pituitary hormone deficiency: genetic variants shift splicing to produce a dominant negative transcription factor isoform. European Journal of Endocrinology, 2021, 185, C19-C25.	1.9	5
226	The hormonal response to stress is not modified by the dramatic decrease in prolactin plasma concentration during surgery for microprolactinoma. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 502-507.	0.9	4
227	Diagnostic etÂprise enÂcharge desÂhyperprolactinÃ©mies â€“ Consensus d'experts deÂlaÂSociÃ©tÃ© franÃ§aise d'endocrinologie (SFE). Annales D'Endocrinologie, 2007, 68, e8-e14.	0.6	4
228	Long-term outcome of macroprolactinomas. Annales D'Endocrinologie, 2016, 77, 641-648.	0.6	4
229	Characterization of adrenocortical tumors by 18F-FDG PET/CT: Does steroid hormone hypersecretion status modify the uptake pattern?. Surgical Oncology, 2018, 27, 231-235.	0.8	4
230	Cost-Utility of Acromegaly Pharmacological Treatments in a French Context. Frontiers in Endocrinology, 2021, 12, 745843.	1.5	4
231	Fully endoscopic endonasal approach for the treatment of intrasellar arachnoid cysts. Pituitary, 2022, 25, 191-200.	1.6	4
232	Adrenal Crisis May Occur Even In Patients With Asymptomatic Covid-19. Endocrine Practice, 2020, 26, 929-930.	1.1	4
233	Lack of delayed neurocognitive side effects of Gamma Knife radiosurgery in acromegaly: the Later-Ac study. European Journal of Endocrinology, 2022, 186, 37-44.	1.9	4
234	A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study. Fertility and Sterility, 1992, 57, 74-80.	0.5	4

#	Article	IF	Citations
235	Cancerous leptomeningitis and familial congenital hypopituitarism. Endocrine, 2016, 52, 231-235.	1.1	3
236	Gamma Knife for Cushing disease â€" time for a reappraisal?. Nature Reviews Endocrinology, 2017, 13, 628-629.	4.3	3
237	Letter to the Editor: â€œWhy We Should Still Treat by Neurosurgery Patients With Cushing Disease and a Normal or Inconclusive Pituitary MRIâ€. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5791-5792.	1.8	3
238	MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushingâ€™s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study. Journal of the Endocrine Society, 2020, 4, .	0.1	3
239	Acromegaly in remission: a view from the partner. European Journal of Endocrinology, 2021, 185, K19-K23.	1.9	3
240	SUN-LB080 ACROSTUDY - Safety and Efficacy of a Cohort of 110 NaÃ¯ve Patients with Acromegaly Treated with Pegvisomant. Journal of the Endocrine Society, 2019, 3, .	0.1	3
241	Chirurgie desÂprolactinomes. Annales D'Endocrinologie, 2007, 68, e35-e36.	0.6	2
242	Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology, 2012, 167, 887-887.	1.9	2
243	Dose-Dependent Dual Role of PIT-1 (POU1F1) in Somatolactotroph Cell Proliferation and Apoptosis. PLoS ONE, 2015, 10, e0120010.	1.1	2
244	Genetic analysis of adult Slovenian patients with combined pituitary hormone deficiency. Endocrine, 2019, 65, 379-385.	1.1	2
245	Medical management of adrenocortical carcinoma: Current recommendations, new therapeutic options and future perspectives. Annales D'Endocrinologie, 2021, 82, 52-58.	0.6	2
246	Women's perceptions of femininity after craniopharyngioma: a qualitative study. Clinical Endocrinology, 2021, 94, 880-887.	1.2	2
247	Predictors of response to long-acting pasireotide in patients with Cushing's disease during a Phase III study. Endocrine Abstracts, 0, , .	0.0	2
248	SAT-291 SIX3 Is Essential for Hypothalamic and Pituitary Development. Journal of the Endocrine Society, 2020, 4, .	0.1	2
249	Ophthalmoplegic complications in transsphenoidal pituitary surgery. Journal of Neurosurgery, 2020, 133, 693-701.	0.9	2
250	Teriparatide administration by the Omnipod pump: preliminary experience from two cases with refractory hypoparathyroidism. Endocrine, 2022, 76, 179-188.	1.1	2
251	Evaluation of three-dimensional MRI exploration of prolactin-secreting microadenomas. Journal of Neuroradiology, 1993, 20, 213-25.	0.6	2
252	Metoclopramide Test in Hyperprolactinemic Women With Polycystic Ovarian Syndrome: Old Wine Into New Bottles?. Frontiers in Endocrinology, 2022, 13, 832361.	1.5	2

#	Article	IF	Citations
253	Authorâ€™s Response: Macroprolactinemia Revisitedâ€”A Study on 106 Patients. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4834-4834.	1.8	1
254	Congenital pituitary hormone deficiencies: role ofLHX3/LHX4genes. Expert Review of Endocrinology and Metabolism, 2008, 3, 751-760.	1.2	1
255	Development of a Prediction Model of Disease Activity in Support of Clinical Practice â€“ the Acrodat Experience. Value in Health, 2015, 18, A708.	0.1	1
256	Combined Pituitary Hormone Deficiency. , 2016, , 177-194.		1
257	Genes important in the fetal development of the pituitary. Current Opinion in Endocrine and Metabolic Research, 2018, 1, 9-12.	0.6	1
258	Fluctuation analysis of postoperative secretory status in patients operated for acromegaly. Annales D'Endocrinologie, 2020, 81, 11-17.	0.6	1
259	Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient. Annales D'Endocrinologie, 2020, 81, 39-43.	0.6	1
260	Role of growth hormone in hepatic and intestinal triglyceride-rich lipoprotein metabolism. Journal of Clinical Lipidology, 2021, 15, 712-723.	0.6	1
261	Ipilimumab-induced hypophysitis in melanoma patients.. Journal of Clinical Oncology, 2012, 30, 8568-8568.	0.8	1
262	3-D-FT Thin-Section MRI of Prolactin-Secreting Microadenomas. , 1994, , 354-363.		0
263	Insuffisance ante hypophysaire post-radique. Annales D'Endocrinologie, 2006, 67, e10-e17.	0.6	0
264	La chirurgie de premiÃ¨re intention a-t-elle encore une place dans le traitement de lâ€™acromÃ©galieÂ?. Annales D'Endocrinologie, 2009, 70, e23-e28.	0.6	0
265	Adenomi ipofisari. EMC - AKOS - Trattato Di Medicina, 2010, 12, 1-12.	0.0	0
266	Tpit, un nouveau membre de la famille des gÃ¨nes Ã boÃ®te T, est impliquÃ© dans la dÃ©ficience isolÃ©e en ACTH. Medecine/Sciences, 2001, 17, 1203-1207.	0.0	0
267	Glucocorticoid receptor antagonists: a therapeutic tool in Cushing's syndrome...to be handled with care. Acta Endocrinologica, 2010, 6, 91-94.	0.1	0
268	Prognostic Factors in Prolactin Pituitary Tumors: Clinical, Histological and Molecular Data from a Series of 94 Patients with a Long Postoperative Follow-Up.. , 2010, , P2-85-P2-85.		0
269	Somatostatin Subtype 2 Receptor (sst2) Overexpression in Gonadotroph Mice Cell Line: Characterization and Effect on Cell Proliferation.. , 2010, , P2-303-P2-303.		0
270	Prolactinomas Resistant to Bromocriptine. Obstetrical and Gynecological Survey, 1997, 52, 235-237.	0.2	0

#	Article	IF	Citations
271	A Novel Mechanism of Hypopituitarism: Defective Interaction of Pit-1 with CBP. Pediatric Research, 1999, 45, 87A-87A.	1.1	0
272	Long-term treatment with pegvisomant (SomavertÂ®): Observations from 2090 acromegaly patients followed in ACROSTUDY. Endocrine Abstracts, 0, , .	0.0	0
273	Pituitary Radiotherapy. , 2019, , 289-293.		0
274	SUN-LB079 Acrostudy - Safety And Treatment Outcomes In 2221 Patients With Acromegaly Treated With Pegvisomant: Real World Experience. Journal of the Endocrine Society, 2019, 3, .	0.1	0
275	Clinical, radiological, and molecular diagnosis of congenital pituitary diseases causing short stature. Archives De Pediatrie, 2022, 28, 28/8S33-28/8S38.	0.4	0